Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy – guidance (TA687)

NICE recommends ribociclib plus fulvestrant for hormone +ve, HER2-ve, locally advanced or metastatic breast cancer in adults who have had previous endocrine therapy only if exemestane plus everolimus is the most appropriate alternative to a CDK 4/6 inhibitor.

Source:

National Institute for Health and Care Excellence